Indonesia's FDA (BPOM) has approved new indication for Theracim
The National Agency of Drug and Food Control (NA-DFC) of Indonesia (BPOM) is the government insitution which is responsible for 3 main functions: supervision of drugs and foods, including development of policies, standards, procedures, and criteria; supervision of drugs and foods before release as preventive action to ensure drugs and foods meet the standards and safety requirements, benefits, and product quality; and supervision during the drugs and foods are released on market and including the law enforcement.
On 19 Oct 2022, Indonesia’s FDA (BPOM) has approved new indication “Locally advanced non-nasopharyngeal Squamous Cell Carcinoma of Head and Neck (SCCHN) (Stage III or IV A/B) in combination with concurrent chemoradiotherapy for Theracim (Nimotuzumab). Nimotuzumab is a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody with intermediate affinity and high specificity. Nimotuzumab inhibits EGF binding to its receptor and inhibits tumor cell growth in vivo and in vitro. Nimotuzumab has potent anti-angiogenic, anti-proliferative and pro-apoptotic effects in EGFR overexpressing tumors.